secwatch / observer
8-K filed December 28, 2023, 6:59 PM ET ticker TCRT CIK 0001107421
leadership confidence high sentiment negative materiality 0.65

Alaunos Therapeutics terminates CEO Kevin S. Boyle; separation payment ~$331,990 plus consulting deal

Alaunos Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kevin S. Boyle, Sr.

Director
TCRT · Alaunos Therapeutics, Inc.
Effective
2023-12-22
Filed
December 28, 2023, 6:59 PM ET
Pursuant to the terms of his employment agreement, upon his termination Mr. Boyle was deemed to automatically resign from the Company’s board of directors.
Departed

Kevin S. Boyle, Sr.

Chief Executive Officer
TCRT · Alaunos Therapeutics, Inc.
Effective
2023-12-22
Filed
December 28, 2023, 6:59 PM ET
On December 22, 2023, Alaunos Therapeutics, Inc. (the “Company”) entered into a Separation and Release Agreement, effective December 22, 2023, with Kevin S. Boyle, Sr. (the “Separation Agreement”), the Company’s Chief Executive Officer, in connection with Mr. Boyle’s termination.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Kevin S. Boyle, Sr. resigned as Director at Alaunos Therapeutics, Inc..

Action
resigned
Role
Director
Exact text from the filing
Pursuant to the terms of his employment agreement, upon his termination Mr. Boyle was deemed to automatically resign from the Company’s board of directors.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Kevin S. Boyle, Sr. was terminated as Chief Executive Officer at Alaunos Therapeutics, Inc..

Action
terminated
Role
Chief Executive Officer
Exact text from the filing
On December 22, 2023, Alaunos Therapeutics, Inc. (the “Company”) entered into a Separation and Release Agreement, effective December 22, 2023, with Kevin S. Boyle, Sr. (the “Separation Agreement”), the Company’s Chief Executive Officer, in connection with Mr. Boyle’s termination.
View on SEC.gov

Alaunos Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-305187
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.